Glioma

15 trials 3 recruiting MedDRA PT
15 Registered trials
3 Recruiting
12 Unique sponsors
11 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
L Oncology (ATC L) 4
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Kinase inhibitor 2 substances
Monoclonal antibody (immune) 2 substances
Alkylating agent 1 substance
Phase III: 2 Phase II: 4 Phase I/II: 6 Phase I: 1 Phase I (Other): 2

Filter these 15 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 15 trials

Phase III

2 trials
  • Institut De Recherches Internationales Servier IRIS Commercial
    VORASIDENIB
    2024-512961-15-00 5 countries 2020 n=71
    Ended
  • Centre Hospitalier Regional Universitaire De Nancy Academic
    FLUORODOPA (18F)
    2022-501688-42-00 1 country 2023 n=88
    Recruiting

Phase II

4 trials
  • Merck Sharp & Dohme LLC Commercial
    LENVATINIB
    2024-512135-80-00 4 countries 2020 n=57
    Ended
  • Philogen S.p.A. Commercial
    LOMUSTINE; ONFEKAFUSP ALFA
    2024-515609-25-00 2 countries n=20 Orphan
    Not authorised
  • Institut Regional Du Cancer De Montpellier Academic
    IMP not specified
    2024-516918-37-00 1 country n=24
    Pending
  • Universitaetsklinikum Aachen AöR Academic
    FLUCICLOVINE (18F); FLUOROETHYLTYROSINE F-18
    2023-507786-26-00 1 country 2024 n=80 Orphan
    Ended

Phase I/II

6 trials
  • Glaxosmithkline Research & Development Limited Commercial
    COBOLIMAB; DOSTARLIMAB
    2024-511350-41-00 6 countries 2025 n=46
    Ended
  • Institut De Recherches Internationales Servier IRIS Commercial
    TEMOZOLOMIDE; VORASIDENIB
    2024-513738-39-00 6 countries 2025 n=17
    Ended
  • Philogen S.p.A. Commercial
    ONFEKAFUSP ALFA; TEMOZOLOMIDE
    2024-516357-46-00 2 countries n=70 Orphan
    Pending
  • Centre Oscar Lambret Academic
    IMP not specified
    2024-513470-22-00 1 country 2019 n=63
    Ended
  • Philogen S.p.A. Academic
    IMP not specified
    2022-501822-39-00 3 countries 2023 n=113
    Recruiting
  • Rigshospitalet Academic
    [68GA]GA-NOTA-AE105
    2024-519723-20-01 1 country n=61
    Pending

Phase I

1 trial
  • BeOne Medicines AG Commercial
    IMP not specified
    2024-515307-19-00 3 countries 2025 n=79
    Recruiting

Phase I (Other)

2 trials
  • Boehringer Ingelheim International GmbH Commercial
    IMP not specified
    2022-501766-22-01 4 countries 2024 n=14
    Ended
  • Hutchmed Ltd. Commercial
    IMP not specified
    2024-516370-30-00 1 country 2021 n=24
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Philogen S.p.A. Commercial 3 Phase II, Phase I/II 1
Institut De Recherches Internationales Servier IRIS Commercial 2 Phase III, Phase I/II 0
BeOne Medicines AG Commercial 1 Phase I 1
Boehringer Ingelheim International GmbH Commercial 1 Phase I (Other) 0
Hutchmed Ltd. Commercial 1 Phase I (Other) 0
Merck Sharp & Dohme LLC Commercial 1 Phase II 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase I/II 0
Institut Regional Du Cancer De Montpellier Academic 1 Phase II 0
Universitaetsklinikum Aachen AöR Academic 1 Phase II 0
Centre Hospitalier Regional Universitaire De Nancy Academic 1 Phase III 1
Centre Oscar Lambret Academic 1 Phase I/II 0
Rigshospitalet Academic 1 Phase I/II 0
New trials by year
2019
1
2020
2
2021
1
2023
2
2024
2
2025
3
← All indication landscapes